EDT/5:30 a.m. PDT to go over the Business's financial outcomes.. Brainstorm Cell Therapeutics provides business upgrade, announces financial outcomes for 2014 BrainStorm Cell Therapeutics Inc. , a respected programmer of adult stem cell systems for neurodegenerative diseases, today announced financial outcomes for the 90 days and calendar year ended December 31, 2014. Tony Fiorino, MD, PhD, CEO of BrainStorm, mentioned, ‘We are extremely happy with the improvement we manufactured in 2014, that was very effective from a clinical along with operational perspective.Professor MacAllister feedback that ‘kidney transplantation transforms the lives of individuals with kidney failure. However, there exists a developing shortage of kidneys for transplantation and the amount of individuals on the transplant list is normally steadily raising. The RIPC procedure is easy, safe, implemented and inexpensive easily; should this trial concur that it improves kidney function, this innovation is a major advantage to kidney transplant recipients. Maximising the features and life-period of the transplanted kidney will optimise the usage of this scarce resource, and therefore raise the number of individuals who can get a transplant.’ Professor Rajesh Thakker, Chairman of the EME Panel said ‘this exciting task is the 1st to end up being funded by the recently established EME program.